(Jinan, China, and Princeton, NJ) KBP BioSciences, a clinical stage biopharma company announced today that it will present clinical data on its lead compounds KBP-5074 and KBP-7072 at the 2016 China BioMed Innovation and Investment Conference to be held in Suzhou, China on Nov 14-16. The following presentations will be delivered:
- KBP-5074 For Chronic Kidney Disease，A Major Unmet Need
- KBP-7072 Tackles Resistant Bacteria
KBP-5074 is a non-steroidal mineralocorticoid receptor antagonist (MRA). Clinical studies have demonstrated that MRAs have therapeutic effects on chronic kidney disease (CKD), hypertension and heart failure. However, marketed MRAs cause serious side effects of hyperkalemia, which can lead to arrhythmia and cardiac arrest. These MRAs are not suitable for CKD patients with various cardiovascular co-morbidities. Globally over 100 million patients suffering these ailments are left with no effective treatments. Phase IIa trials showed that KBP-5074 has highly promising hyperkalemia profile, making it the best hope for CKD patients as well as CKD patients with hypertension and heart failure co-morbidities.
KBP-7072 is a new generation broad spectrum antibiotics aimed at multi-drug resistant bacteria. In addition to major resistant strains such as MRSA and VRE, KBP-7072 is highly potent against Gram negative pathogen Acinetobacter. The bacterium is increasingly common in hospital and community settings causing high mortality rate. There is no effective therapy for this deadly pathogen. KBP-7072 has good PK profile, available in both oral and injectable formulations, making it ideal for various infections. Phase I trial in the US showed that KBP-7072 was safe and generally well tolerated. The oral formulation has good bioavailability, and long half-life in human. Even at the highest dose tried, no GI adverse events were observed.